header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-23879
Fish name: zn1Tg
Genotype: zn1Tg
Targeting Reagent: none
Current Source: Zygogen Research Department
HUMAN DISEASE MODELED by zn1Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Chen et al., 2017
cancer xenotransplantation Berens et al., 2017
GENE EXPRESSION
Gene expression in zn1Tg
RNA expression
Expressed Gene Structure Conditions Figures
acsbg2 standard conditions Fig. 3 with image from Gomez et al., 2012
aff3 standard conditions Fig. 3 with image from Gomez et al., 2012
ankdd1a standard conditions Fig. 3 with image from Gomez et al., 2012
arhgap27l standard conditions Fig. 3 with image from Gomez et al., 2012
arhgap31 standard conditions Fig. 3 with image from Gomez et al., 2012
cald1a standard conditions Fig. 3 with image from Gomez et al., 2012
capn8 standard conditions Fig. 3 with image from Gomez et al., 2012
ccdc135 standard conditions Fig. 3 with image from Gomez et al., 2012
cd93 standard conditions Fig. 3 with image from Gomez et al., 2012
cers3b standard conditions Fig. 3 with image from Gomez et al., 2012
cntn4 standard conditions Fig. 3 with image from Gomez et al., 2012
dgki standard conditions Fig. 3 with image from Gomez et al., 2012
fhl3a standard conditions Fig. 3 with image from Gomez et al., 2012
gpr183a standard conditions Fig. 3 with image from Gomez et al., 2012
grtp1b standard conditions Fig. 3 with image from Gomez et al., 2012
arhgap45b standard conditions Fig. 3 with image from Gomez et al., 2012
ifit12 standard conditions Fig. 3 with image from Gomez et al., 2012
irf9 standard conditions Fig. 3 with image from Gomez et al., 2012
klhl4 standard conditions Fig. 3 with image from Gomez et al., 2012
mhc1uea standard conditions Fig. 3 with image from Gomez et al., 2012
myl9a standard conditions Fig. 3 with image from Gomez et al., 2012
myo1f standard conditions Fig. 3 with image from Gomez et al., 2012
myofl standard conditions Fig. 3 with image from Gomez et al., 2012
nrgnb standard conditions Fig. 3 with image from Gomez et al., 2012
rasa4 standard conditions Fig. 3 with image from Gomez et al., 2012
rassf4a standard conditions Fig. 3 with image from Gomez et al., 2012
rgl2 standard conditions Fig. 3 with image from Gomez et al., 2012
samd10b standard conditions Fig. 3 with image from Gomez et al., 2012
sept5b standard conditions Fig. 3 with image from Gomez et al., 2012
sh3bp4 standard conditions Fig. 3 with image from Gomez et al., 2012
si:ch211-250g4.3 standard conditions Fig. 3 with image from Gomez et al., 2012
sowahd standard conditions Fig. 3 with image from Gomez et al., 2012
tagapb standard conditions Fig. 3 with image from Gomez et al., 2012
tmem88a standard conditions Fig. 3 with image from Gomez et al., 2012
tmem119b standard conditions Fig. 3 with image from Gomez et al., 2012
tmem151a standard conditions Fig. 3 with image from Gomez et al., 2012
xirp2a standard conditions Fig. 3 with image from Gomez et al., 2012
zgc:162941 standard conditions Fig. 3 with image from Gomez et al., 2012
PHENOTYPE
Phenotype in zn1Tg
Phenotype Conditions Figures
angiogenesis disrupted, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
dorsal aorta decreased diameter, abnormal chemical treatment: wortmannin Fig. S8 from Zhao et al., 2013
dorsal aorta decreased diameter, abnormal chemical treatment: LY294002 Fig. 3 from Zhao et al., 2013
dorsal aorta decreased diameter, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 from Zhao et al., 2013
dorsal aorta decreased diameter, abnormal chemical treatment: phenylarsine oxide Fig. S5 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal chemical treatment: wortmannin Fig. S8 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal chemical treatment: phenylarsine oxide Fig. S5 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 from Zhao et al., 2013
dorsal aorta blood vessel lumenization decreased process quality, abnormal chemical treatment: LY294002 Fig. 3 from Zhao et al., 2013
intersegmental vessel morphology, abnormal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009
motor neuron axon guidance process quality, normal chemical treatment: butan-1-ol Fig. 7 with image from Zeng et al., 2009

CITATIONS  (49)